Saghmos Therapeutics

Saghmos Therapeutics is participating in the 3rd Annual Kidney Virtual Conference hosted by H.C. Wainwright. Please join me on Monday, July 15, 2024 at 11 a.m. ET via live webcast (https://lnkd.in/ez5GFpX6) to learn more about our Phase 3-ready cardiovascular-kidney-metabolic modular, ST-62516. Saghmos is developing ST-62516 for reducing the risk of complications after PCI, a major unmet medical need with no FDA-approved drugs and a multi-billion dollar revenue potential.  Stephen Grant, M.D., former Deputy Director of FDA’s Division of Cardiology and Nephrology and Saghmos’ Chief Regulatory Officer and I will be available for 1x1 virtual meetings. Reach out via LinkedIn message to schedule a meeting. A replay of the webcast will be available shortly after the presentation. #CKM #CardiovascularKidneyMetabolic #Cardiorenal #AcuteKidneyInjury #AKI #PCI #CVRM #ChronicKidneyDisease #CKD #Dialysis

Our 3rd Annual Kidney Conference will take place virtually on July 15th. Join us for a day of insightful panel discussions to stay informed on developments in the kidney space, company 1x1 meetings, and hear updates from the following participating companies: Akebia Therapeutics, Aurinia Pharmaceuticals Inc., CalciMedica, Kezar Life Sciences, POXEL, Regulus Therapeutics, Rockwell Medical, Inc., Saghmos Therapeutics, Travere Therapeutics, Unicycive Therapeutics, Vera Therapeutics, Inc., Walden Biosciences, and ZyVersa Therapeutics Inc. For more information and to register, visit: https://lnkd.in/eJeRyQHW

Productive discussion on managing the runway with #biotech CEOs Paul Peter Tak, MD PhD FMedSci Candel Tx, Anna Kazanchyan, M.D. Saghmos Therapeutics, Dror Harats ImmuneWalk Therapeutics, Brendan Smith Doppler Bio & Pratik Shah Design Therapeutics #longwoodhealthcareleaders

Excited to announced the issuance of the second U.S patent for our Phase 3-ready cardiorenal-metabolic modulator ST-62516. The patent provides for exclusivity through 2037, with broad claims for the reduction of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) in patients with Cardiovascular-Kidney-Metabolic (CKM) Syndrome Undergoing Procedures with contrast dyes. #CKM #cardiorenal #AKI #PCI

We are excited to announce Saghmos Therapeutics' participation at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. Please join me on June 12th at 3:20pm ET to learn more about our Phase 3-ready cardio-renal asset, ST-62516 (trimetazidine) for reducing the risk of cardiorenal complications after PCI. Dr. Stephen Grant, former Deputy Director of the FDA's Division of Cardiology and Nephrology and currently our Chief Regulatory Officer, and I will be available for 1x1 meetings June 10-12th - please get in touch via LinkedIn message, if interested. The presentation will be webcast live at: https://lnkd.in/eQFHBkhj, with a replay available shortly thereafter. https://lnkd.in/epzrwCpw

We are excited to announce the issuance of Japanese Patent No. 7474463 for our Phase 3-ready cardiorenal metabolic modulator ST-62516 (trimetazidine). The patent provides exclusivity through 2037, with broad claims for the reduction of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) undergoing procedures with contrast dyes. #cardiorenal #acutekidneyinjury #Phase3 #cardiovascularkidneymetabolic #CKM #CKD #AKI https://lnkd.in/exyTAYkp

“We are delighted to work with Saghmos. Acute kidney injury and its cardiac and kidney sequelae are an area of high unmet need in patients undergoing PCI who have pre-existing cardiovascular disease, kidney disease and diabetes,” said Schuyler Jones, M.D., who is the principal investigator and an interventional cardiologist with the DCRI. “We are excited about the opportunity to collaborate and provide input on the design of the Phase 3 study of ST-62516 to address this need and become the standard of care.”

We are excited to announce a Notice of Allowance from the Japanese Patent Office for a patent for our Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator. The patent will provide exclusivity through 2037, with broad claims for the reduction of acute kidney injury in patients with chronic kidney disease (CKD) undergoing procedures with contrast dyes. https://lnkd.in/egWKrZBK

Excited to attend the Leerink Partners 2024 Global Biopharma Conference! #GBC2024

Yet another highly insightful and informative panel discussion on Day 2 at the R&D Leadership Summit: “R&D for a Large, Heterogenous and Growing Global Market.” Many thanks to expert panelists Houman Ashrafian, Meeta Chatterjee, and Badhri Srinivasan for a deeply thoughtful and thought-provoking discussion and many thanks to Mathai Mammen, M.D., Ph.D. for masterfully moderating the panel. Valerie Bowling, Tracey Kimball - strong applause for your and your team’s strategic and operational prowess that makes the R&D Leadership Summit the amazing event that it is!